483 related articles for article (PubMed ID: 34445385)
21. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Barkdull S; Brownell I
Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
[TBL] [Abstract][Full Text] [Related]
22. Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers.
Wang G; Chai Q; Xiao Y; Peng W; Teng M; Wang J; Lin H; Su X; Wu L
Front Immunol; 2020; 11():607416. PubMed ID: 33584678
[TBL] [Abstract][Full Text] [Related]
23. Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
Ricco G; Andrini E; Siepe G; Mosconi C; Ambrosini V; Ricci C; Casadei R; Campana D; Lamberti G
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638968
[TBL] [Abstract][Full Text] [Related]
24. [Periocular Merkel Cell Carcinoma - an overview of clinical aspects and current therapeutic options].
Esser E; Grünewald I; Mihailovic N
Laryngorhinootologie; 2024 Jun; 103(6):404-412. PubMed ID: 38128577
[TBL] [Abstract][Full Text] [Related]
25. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
Kanemaru H; Fukushima S; Mizukami Y; Sawamura S; Nakamura K; Honda N; Makino K; Kajihara I; Aoi J; Makino T; Kawasaki T; Kudou E; Jhono M; Ito T; Arima N; Ihn H
J Dermatol; 2020 Nov; 47(11):1317-1321. PubMed ID: 32794263
[TBL] [Abstract][Full Text] [Related]
26. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
27. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.
Ricci C; Righi A; Ambrosi F; Gibertoni D; Maletta F; Uccella S; Sessa F; Asioli S; Pellilli M; Maragliano R; La Rosa S; Papotti MG; Asioli S
Endocr Pathol; 2020 Mar; 31(1):21-32. PubMed ID: 31808008
[TBL] [Abstract][Full Text] [Related]
29. Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8
Jing L; Ott M; Church CD; Kulikauskas RM; Ibrani D; Iyer JG; Afanasiev OK; Colunga A; Cook MM; Xie H; Greninger AL; Paulson KG; Chapuis AG; Bhatia S; Nghiem P; Koelle DM
Cancer Immunol Res; 2020 May; 8(5):648-659. PubMed ID: 32179557
[TBL] [Abstract][Full Text] [Related]
30. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.
Feldmeyer L; Hudgens CW; Ray-Lyons G; Nagarajan P; Aung PP; Curry JL; Torres-Cabala CA; Mino B; Rodriguez-Canales J; Reuben A; Chen PL; Ko JS; Billings SD; Bassett RL; Wistuba II; Cooper ZA; Prieto VG; Wargo JA; Tetzlaff MT
Clin Cancer Res; 2016 Nov; 22(22):5553-5563. PubMed ID: 27166398
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for Merkel cell carcinoma: a turning point in patient care.
Chan IS; Bhatia S; Kaufman HL; Lipson EJ
J Immunother Cancer; 2018 Mar; 6(1):23. PubMed ID: 29566749
[TBL] [Abstract][Full Text] [Related]
32. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
33. A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma.
Walsh NM; Fleming KE; Hanly JG; Dakin Hache K; Doucette S; Ferrara G; Cerroni L
Hum Pathol; 2016 Jun; 52():190-6. PubMed ID: 26980039
[TBL] [Abstract][Full Text] [Related]
34. Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma.
Rubin KM; Hoffner B; Bullock AC
Semin Oncol Nurs; 2019 Oct; 35(5):150924. PubMed ID: 31514991
[TBL] [Abstract][Full Text] [Related]
35. Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report.
Abdallah N; Nagasaka M; Chowdhury T; Raval K; Hotaling J; Sukari A
Oral Oncol; 2019 Dec; 99():104350. PubMed ID: 31277904
[TBL] [Abstract][Full Text] [Related]
36. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
[TBL] [Abstract][Full Text] [Related]
37. γδ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival.
Gherardin NA; Waldeck K; Caneborg A; Martelotto LG; Balachander S; Zethoven M; Petrone PM; Pattison A; Wilmott JS; Quiñones-Parra SM; Rossello F; Posner A; Wong A; Weppler AM; Shannon KF; Hong A; Ferguson PM; Jakrot V; Raleigh J; Hatzimihalis A; Neeson PJ; Deleso P; Johnston M; Chua M; Becker JC; Sandhu S; McArthur GA; Gill AJ; Scolyer RA; Hicks RJ; Godfrey DI; Tothill RW
Cancer Immunol Res; 2021 Jun; 9(6):612-623. PubMed ID: 33674358
[TBL] [Abstract][Full Text] [Related]
38. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
Paulson KG; Bhatia S
J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
[TBL] [Abstract][Full Text] [Related]
39. New perspectives in Merkel cell carcinoma.
Del Marmol V; Lebbé C
Curr Opin Oncol; 2019 Mar; 31(2):72-83. PubMed ID: 30694842
[TBL] [Abstract][Full Text] [Related]
40. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
Shirley M
Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]